Search results
Results from the WOW.Com Content Network
Cutaneous vasculitis is the most common type of vasulitis amongst those with systemic lupus erythematosus. [7] The clinical presentation is variable and can include superficial ulcerations, splinter hemorrhages, panniculitis, macules, erythema with necrosis or erythematous plaques, cutaneous infarction, livedo reticularis, bullous lesions of the extremities or urticaria lesions, papulonodular ...
Patients with cSLE may present with tissue-injuring and blood vessel-injuring (termed lupus vasculitis) inflammation in the: a) kidneys, causing various types of kidney damages e.g., lupus nephritis and kidney failure, and thereby hypertension, i.e., high blood pressure; [1] [11] [12] b) central nervous system, causing headaches, seizures ...
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [1]
Here's what vasculitis is and what the symptoms and treatments are. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to ...
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs. The most common and most severe form is systemic lupus erythematosus.
Around 90% of people with lupus are women. Common symptoms include extreme fatigue, joint pain or skin rashes. In rare cases, the disease may lead to kidney or heart damage, or weaken the immune ...
Necrotizing vasculitis, also called systemic necrotizing vasculitis, [1] is a general term for the inflammation of veins and arteries that develops into necrosis and narrows the vessels. [ 2 ] Tumors , medications, allergic reactions , and infectious organisms are some of the recognized triggers for these conditions, even though the precise ...
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...